.png){kind=small}
01 CORE TECHNOLOGY
EVIA'S BREAKTHROUGH TECHNOLOGY
Cell Reprogramming as an Engine for EV Drug Discovery
Our core technology is cell reprogramming, a process that reverts mature cells into multipotent progenitor cells without genetic modification.
EVIA was the first to successfully reprogram mature hepatocytes into liver progenitor cells, known as CLiPs, in vitro.
These progenitor cells produce extracellular vesicles containing bioactive cargo, including microRNAs, proteins and other functional molecules derived from their source cells.By combining cell reprogramming with EV research, EVIA aims to discover and develop a new generation of cell-free therapeutics.
Katsuda et al., 2017, Cell Stem Cell
01 / CELL REPROGRAMMING
Reprogramming mature hepatocytes into liver progenitor cells
EVIA's foundational technology converts mature hepatocytes into proliferative liver progenitor cells without genetic modification. These chemically induced liver progenitor cells provide a renewable source for research and therapeutic development.
WHY REPROGRAMMING MATTERS
Progenitor cells unlock more potent and scalable EV development
-
Mature cells transform into stem-like progenitors with superior regenerative power
-
Progenitors produce higher-quality EVs
-
Enables increased efficacy and scalable production
Illustration: Juntaro Matsuzaki, Keio University
01
Mature Cells
Selected cell sources
02
Progenitor Cells
Proprietary reprogramming
03
Therapeutic EVs
Bioactive, cell-free candidates
02 LEAD PROGRAM
LIVER FIBROSIS & MASH
hCLiP-derived Extracellular Vesicles
EVIA's lead program is developing extracellular vesicles derived from human chemically induced liver progenitor cells, known as hCLiPs.
Preclinical PoC
Demonstrated across multiple animal models
The program is being advanced as a potential cell-free treatment for liver fibrosis and MASH.
03 SCIENTIFIC FOUNDATION
Built on Leading Science and
Proprietary Technology
EVIA's research is supported by an extensive intellectual property portfolio, peer-reviewed scientific publications and collaborations with leading academic and medical institutions in Japan. Our core technologies are protected by granted patents in major global markets.
Cell- Free
Selected cell sources
Multi-Pathway Action
Preclinical PoC
Global IP
Granted patents in major markets
SELECTED PUBLICATIONS
Partnering with EVIA
Advancing the Next Generation
of EV Therapeutics, Together.
We welcome opportunities to collaborate with pharmaceutical and biotechnology companies seeking to develop innovative extracellular vesicle therapeutics.
04 Our Offices
UNITED STATES
11500 S. Eastern Ave #150,
Henderson, Nevada 89052
JAPAN
c/o Octave Japan Co., Ltd., Midtown Tower 18F
9-7-1 Akasaka, Minato-ku, Tokyo, 107-6218